Abstract
The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma. The major dose-limiting toxicity was granulocytopenia. There was one toxic death from sepsis. Central nervous system and renal toxicity occurred infrequently, perhaps as a result of the continuous-infusion schedule. This regimen is being evaluated further in advanced disease, the adjuvant setting, and in combination with bone marrow colony-stimulating factors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Brain Neoplasms / secondary
-
Brain Neoplasms / therapy
-
Combined Modality Therapy
-
Dacarbazine / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Evaluation
-
Female
-
Humans
-
Ifosfamide / administration & dosage
-
Lung Neoplasms / secondary
-
Lung Neoplasms / surgery
-
Male
-
Mesna / administration & dosage
-
Middle Aged
-
Remission Induction
-
Sarcoma / drug therapy*
-
Sarcoma / mortality
-
Sarcoma / secondary
-
Sarcoma / surgery
-
Survival Rate
Substances
-
Dacarbazine
-
Doxorubicin
-
Mesna
-
Ifosfamide